CARE Center

HPTN 077

HPTN 077 logo where the 0 in 077 is a circular life preserver

A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women

OBJECTIVE

This study evaluated the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.

STUDY TYPE: HIV Prevention

DURATION: February 2015 - July 2018

PHASE: IIA

STUDY DESIGN: Randomized, parallel assigned, quadrupal masked interventional study

POPULATION: Healthy volunteers aged 18 - 65 years old

NUMBER OF SITES: 8

SITE LOCATIONS: US, Brazil, Malawi, and South Africa

STATUS: Complete

RESULTS

Mathead for journal acticle titled, "Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial"
Access the full article here
Masthead for a research article titled, "Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial."
Access the full article here
A masthead for a journal article titled, "A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP."
Access the full article here
A masthead for journal article titled, "Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077"
Access the full article here
A masthead for a journal article titled, "Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial"
Access the full article here